Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Plus Therapeutics Inc (NQ: PSTV )

1.800 -0.060 (-3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Plus Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
21 Stocks Moving in Thursday's Pre-Market Session
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market... 
Via Benzinga
Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial
The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ: PSTV) to proceed to the eighth cohort of Phase 1 dose-escalation ReSPECT trial... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Applied Genetic (NASDAQ:AGTC) sha... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) rose 58.3% to $78.90 in pre-market trading. Nicholas Jason Singer disclosed a 9.13% passive stake in Brooklyn... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Acutus Medical (NASDAQ:AFIB) sto... 
Via Benzinga
Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial
Plus Therapeutics Inc (NASDAQ: PSTV) has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For July 22, 2021
Companies Reporting Before The Bell • Champions Oncology, Inc. - Common Stock (NASDAQ:CSBR) is estimated to report earnings for its fourth quarter. • MarineMax,... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock moved upwards by 23.75% to $8.18 during Wednesday's after-market session. Today's trading volume for this security ended up... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 11.8% to $1.61 during Friday's pre-market session. The market value of their outstanding shares is at $205.... 
Via Benzinga
11 Stocks Moving In Thursday's After-Hours Session
Gainers Mattel (NASDAQ: MAT) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. Skechers (NYSE: SKX) shares are trading higher... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Ocugen (NASDAQ:OCGN) stock moved upwards by 7.1% to $9.95 during Thursday's after-market session. At the close, Ocugen's trading volume reached 7.6 million shares... 
Via Benzinga
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
Earnings Scheduled For April 22, 2021
Companies Reporting Before The Bell • Republic First Bancorp (NASDAQ:FRBK) is estimated to report quarterly earnings at $0.05 per share on revenue of $36.85 million.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.